Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration [Yahoo! Finance]
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Guardant Health (GH) is back in focus after the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for BRAF V600E-mutant metastatic colorectal cancer and the company announced a multi-year collaboration with Merck. See our latest analysis for Guardant Health. These regulatory and partnership updates come after a strong run, with the latest share price at $114.04, a 30 day share price return of 11.65% and a 1 year total shareholder return of 142.74%. However, the 5 year total shareholder return of 29.86% loss shows the longer term journey has been much more volatile. If Guardant's story has your attention, it could be a good moment to look across the sector and check out healthcare stocks as potential next ideas. With the shares already up sharply over the past year, a fresh FDA approval, a new Merck collaboration and an estimated intrinsic discount of about 23% now on the table, is this a genuine opening, or is the market already pricing in future growth
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions [Yahoo! Finance]Yahoo! Finance
- Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment DecisionsBusiness Wire
- Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026Business Wire
- Alger Small Cap Focus Fund Q4 2025 Portfolio Update [Seeking Alpha]Seeking Alpha
GH
Earnings
- 10/29/25 - Beat
GH
Sec Filings
- 2/2/26 - Form 4
- 1/22/26 - Form 4
- 1/22/26 - Form 4
- GH's page on the SEC website